Alexander Ginzburg, the scientific director of the Gamaleya National Research Center for Epidemiology and Microbiology, reported that only a slight increase in temperature was recorded after the administration of the vaccine against cancer
Alexander Gintsburg, the scientific director of the Gamaleya National Research Center for Epidemiology and Microbiology, reported that only a slight increase in temperature was observed after the administration of the cancer vaccine.
According to him, the first patient to receive the cancer vaccine did not experience any serious adverse reactions after the vaccination, with only a single instance of a slight rise in body temperature.
He says: "There were no side effects. There was a slight, one-time increase in temperature, as usually happens when giving any vaccine, nothing more."
Ginzburg explains that the patient who received the vaccine has stage three cancer.
It is reported that on April 1st, the first patient in Russia received the personalized cancer vaccine, "Nyonkovac," intended for the treatment of melanoma skin cancer. It was produced by the National Research Center for Radiological Medicine of the Russian Ministry of Health and developed in collaboration with the Gamaleya National Research Center and the Blokhin National Research Center for Oncology.
This drug is used to treat adult patients with inoperable or metastatic melanoma.
